Molecular and immunohistochemical characteristics of BM were consistent with data reported in Literature: out of 22 analysed BM, HER2+ was documented in four (18%); three (14%) carried a BRAFV600E mutation; two (9%) displayed MSI-H: therefore, HER2, BRAFV600E and MSI-H enrichment in BM from CRC was confirmed. Here, ERBB2 is linked to colorectal carcinoma.